Results 1 to 10 of about 3,244,110 (380)
Applications of Single-Cell Omics in Tumor Immunology. [PDF]
Front Immunol, 2021 The tumor microenvironment (TME) is an ecosystem that contains various cell types, including cancer cells, immune cells, stromal cells, and many others. In the TME, cancer cells aggressively proliferate, evolve, transmigrate to the circulation system and
Liu J +7 more
europepmc +4 more sources
High-content CRISPR screening in tumor immunology [PDF]
Frontiers in Immunology, 2022 CRISPR screening is a powerful tool that links specific genetic alterations to corresponding phenotypes, thus allowing for high-throughput identification of novel gene functions.
Erin A. Holcomb +16 more
doaj +3 more sources
Tumor-derived microparticles in tumor immunology and immunotherapy. [PDF]
Eur J Immunol, 2020 Microvesicles or microparticles, a type of cytoplasm membrane‐derived extracellular vesicles, can be released by cancer cells or normal cell types. Alteration of F‐actin cytoskeleton by various signals may lead to the cytoplasm membrane encapsulating ...
Ma J, Zhang H, Tang K, Huang B.
europepmc +4 more sources
The Potential Regulatory Roles of Circular RNAs in Tumor Immunology and Immunotherapy. [PDF]
Front Immunol, 2020 Circular RNAs (circRNAs) are covalently closed RNA molecules in eukaryotes with features of high stability, tissue-specific and cell-specific expression. According to their biogenesis, circRNAs are mainly classified into five types, i.e. exonic circRNAs (
Fang Z, Jiang C, Li S.
europepmc +4 more sources
Tumor Immunology and Tumor Evolution: Intertwined Histories [PDF]
Immunity, 2020 Cancer is a complex disease whose outcome depends largely on the cross-talk between the tumor and its microenvironment. Here, we review the evolution of the field of tumor immunology and the advances, in lockstep, of our understanding of cancer as a disease.
Jérôme Galon, Daniela Bruni
exaly +7 more sources
Organoid Models of Tumor Immunology. [PDF]
Trends Immunol, 2020 Cellular interactions in the tumor microenvironment (TME) significantly govern cancer progression and drug response. The efficacy of clinical immunotherapies has fostered an exponential interest in the tumor immune microenvironment, which in turn has engendered a pressing need for robust experimental systems modeling patient-specific tumor-immune ...
Yuki K, Cheng N, Nakano M, Kuo CJ.
europepmc +6 more sources
Tumor Immunology and Immunotherapy for Head and Neck Squamous Cell Carcinoma. [PDF]
J Dent Res, 2018 The immune system plays an important role in the evolution of malignancy and has become an important target for novel antineoplastic agents. This review article focuses on key features of tumor immunology, including the role of immunotherapy in general ...
Moskovitz JM, Ferris RL.
europepmc +4 more sources
From Tumor Immunology to Immunotherapy in Gastric and Esophageal Cancer. [PDF]
Int J Mol Sci, 2018 Esophageal and gastric cancers represent tumors with poor prognosis. Unfortunately, radiotherapy, chemotherapy, and targeted therapy have made only limited progress in recent years in improving the generally disappointing outcome.
Vrána D +8 more
europepmc +4 more sources
In ovo model in cancer research and tumor immunology. [PDF]
Front Immunol, 2022 Considering cancer not only as malignant cells on their own but as a complex disease in which tumor cells interact and communicate with their microenvironment has motivated the establishment of clinically relevant 3D models in past years.
Miebach L, Berner J, Bekeschus S.
europepmc +2 more sources
Lung cancer in never smokers: Tumor immunology and challenges for immunotherapy. [PDF]
Front Immunol, 2022 Lung cancer is the second most common and the most lethal malignancy worldwide. It is estimated that lung cancer in never smokers (LCINS) accounts for 10-25% of cases, and its incidence is increasing according to recent data, although the reasons remain ...
de Alencar VTL +4 more
europepmc +2 more sources